RME prior authorization rationale

Rapid maxillary expansion (RME) for pediatric OSA may be subject to local plan authorization. Prior authorization for RME should include documentation of transverse maxillary constriction (e.g., narrow/high-arched palate or crossbite), baseline AHI, prior adenotonsillectomy status (if performed), and a discussion that RME evidence is limited and randomized data do not convincingly show benefit over watchful waiting. Consideration should be given to the dental/orthodontic benefit exclusion in many medical plans; verify member benefits prior to authorization.

• Document transverse maxillary deficiency (narrow/high-arched palate)
• Provide baseline AHI and prior AT status
• Discuss limited RCT evidence and potential dental benefit exclusion

Pre-operative counseling and post-operative monitoring documentation

Children with cerebral palsy (and other high-risk conditions) undergoing adenotonsillectomy should have documented pre-operative counseling about increased peri-operative respiratory risks and a documented post-operative monitoring plan. Authorization and care plans should reflect the need for close inpatient observation, higher risk of respiratory complications, and discussion of possible additional surgical management (including tracheostomy) if OSA persists.

• Document counseling of family regarding increased peri-operative risk
• Document plan for close post-operative monitoring and potential ICU care
• Note possibility of further interventions if OSA persists

Prior authorization not specified in this section

This section does not itself establish new prior authorization rules for all procedures or devices listed elsewhere in the policy. Providers must follow specific plan provisions and pre-authorization tools for the member's benefit plan.

• Check the member's benefit plan for any applicable prior authorization requirements
• Use plan-specific authorization portals or contact the plan for clarification

Prior authorization guidance

Clinical Policy Bulletins are intended to assist administration of plan benefits and do not replace plan-specific requirements. Providers should follow the health plan's procedures for prior authorization, billing, and documentation; if in doubt, obtain prior authorization before performing services.

• CPBs do not constitute a contract or guarantee of coverage
• Obtain plan-specific prior authorization when required

Noncovered procedures / code denials (denial risk)

Procedures and services listed in the policy as not covered or considered experimental/investigational are denial risks if submitted for those indications. Verify coding and indications against the CPB before authorization or claim submission.

• Examples of not-covered CPT ranges: 30000-30999 (nasal surgeries), 30801-30802 (somnoplasty), 41130 (hemiglossectomy), 41512 (Repose system tongue suspension), 42140/42160 (uvulectomy/destruction of palate/uvula), 42890/42950 (pharyngeal procedures)
• Montelukast has no specific HCPCS/CPT code listed and use for OSA is off-label (see montelukast callouts)

Regulatory and prior‑therapy context for hypoglossal nerve stimulation (HNS)

For hypoglossal nerve stimulation (HNS/UAS) in pediatric patients, document that FDA criteria and prior-therapy conditions are met: age 13–18, Down syndrome diagnosis, AHI >10 and <50, absence of complete concentric collapse at the soft palate, contraindication to or ineffective adenotonsillectomy, and confirmed failure or intolerance of PAP despite attempts to improve compliance. Prior use of standard therapies and consideration of alternative/adjunct treatments should be evident in the record.

• Age documented (13–18 years) and diagnosis of Down syndrome
• Baseline AHI and documentation of lack of complete concentric collapse (e.g., DISE)
• Documentation of adenotonsillectomy contraindication or failure
• Evidence of PAP failure or intolerance and attempts to improve compliance
• Notes on consideration of other therapies

RME evidence insufficiency (denial risk)

The evidence base for RME is mixed: uncontrolled case series show short‑term improvements but controlled randomized data are sparse and one RCT did not show superiority versus watchful waiting. Because long‑term effects and reproducibility are uncertain, payers may deny coverage without strong, patient‑specific documentation supporting use.

• Cite RME studies showing short‑term AHI and LSAT improvements in selected patients
• Note lack of convincing RCT evidence and need for reproducible inclusion criteria

Montelukast — off‑label use risk and documentation

Montelukast and intranasal corticosteroids have shown short‑term improvements in AHI in some trials for mild pediatric OSA, but montelukast is not FDA‑approved for OSA and use is off‑label. Document indication, duration, expected benefit, and monitor for adverse effects (including behavioral changes). Authorization or coverage may be scrutinized given off‑label status.

• Document diagnosis of mild OSA and rationale for medical therapy
• Record baseline and follow-up PSG/AHI when available
• Monitor and document adverse effects (e.g., behavioral side effects)

Incomplete PSG documentation can affect coverage decisions

Incomplete or absent pre‑ or post‑operative polysomnography (PSG/NPSG) can affect coverage decisions and the applicability of evidence. When studies cited in support of interventions lack complete PSG data, plans may require objective testing (pre‑ and/or post‑op PSG) to substantiate medical necessity and outcomes.

• Provide pre‑operative PSG when indicated by policy or clinical circumstance
• Provide post‑operative PSG for high‑risk patients or when residual symptoms persist (timing per policy recommendations)
• Document reasons if PSG cannot be obtained and alternative objective data

Background / not directly applicable to authorization

Background sections and some referenced studies do not directly create coverage rules. Use the background evidence to support medical necessity decisions, but rely on the policy criteria and plan benefits for authorization determinations.

• Background evidence informs but does not replace policy criteria
• Follow the policy's documented selection criteria for covered services

Polysomnography documentation (diagnosis and post‑op)

Polysomnography (PSG/NPSG) is the gold standard for diagnosis and monitoring of pediatric OSA. For authorization, document that PSG was facility‑based, attended by a technologist, and interpreted by a qualified physician, and that the indication for testing matches policy criteria (diagnostic reasons or post‑operative assessment).

• Confirm facility‑based, attended overnight PSG/NPSG
• Record the specific indication for testing per policy (diagnosis, post‑op assessment, etc.)
• Attach physician interpretation and technologist attendance notes

Required clinical documentation for HNS candidacy

When requesting authorization for hypoglossal nerve stimulation (HNS/UAS), include the required clinical documentation to establish candidacy: patient age, diagnosis (Down syndrome), baseline AHI, DISE findings ruling out complete concentric collapse at the soft palate, documentation of prior adenotonsillectomy status or contraindication, and detailed records of PAP therapy failure or intolerance and measures taken to improve adherence.

• Age 13–18 and Down syndrome diagnosis documented
• Baseline AHI (>10 and <50) with supporting PSG
• DISE or equivalent documentation demonstrating absence of complete concentric collapse at the soft palate
• Records of adenotonsillectomy status or contraindication
• Detailed documentation of PAP trials, adherence efforts, and intolerance

RME patient selection and follow‑up documentation

For RME patient selection and follow‑up, document transverse maxillary deficiency (narrow/high‑arched palate or crossbite), baseline PSG/AHI, prior adenotonsillectomy status, orthodontic treatment plan, and follow‑up sleep testing or clinical assessments to demonstrate response and durability.

• Document transverse maxillary deficiency and orthodontic diagnosis
• Provide baseline AHI and plan for follow‑up PSG or objective assessment
• State prior AT status and rationale for RME as adjunctive therapy

TORS‑TBR documentation requirements

For TORS‑TBR (transoral robotic surgery tongue‑base resection) with tongue‑base suspension, include documentation of DISE‑confirmed tongue‑base collapse, preoperative AHI demonstrating moderate‑to‑severe OSA (e.g., AHI >15 in cited studies), and prior failure of CPAP. Discuss expected benefits, risks, and alternative therapies in the record.

• DISE confirming tongue‑base collapse and glossoptosis
• Preoperative AHI and severity documented
• Evidence of CPAP failure or intolerance
• Informed consent noting expected benefits/risks and potential additional procedures

Provider responsibility for medical advice and treatment

Treating providers are solely responsible for medical advice and treatment decisions. Clinical Policy Bulletins are informational and do not replace clinical judgment. When submitting authorization requests, ensure documentation supports the clinical decision and plan adherence to policy criteria.

• Providers must document clinical rationale and informed consent
• Use CPB as guidance but rely on clinical judgment for patient care

Medical therapy (montelukast / intranasal steroid) as an initial option

Medical therapy (e.g., montelukast, intranasal steroids) may be appropriate as an initial option for selected children with mild OSA or as temporizing therapy while awaiting other interventions. When used, document indication, planned duration, monitoring, and criteria for escalation to surgical or CPAP therapy.

• Document mild OSA diagnosis and rationale for medical therapy
• Record planned duration and monitoring strategy
• Specify criteria for escalation to surgery or CPAP